About Biohaven Pharmaceutical Holding Co
Biohaven Pharmaceutical (NYSE:BHVN) focuses on developing innovative therapies for debilitating neurological and neuropsychiatric diseases, including rare disorders. The company's research and development efforts are primarily concentrated on advancing a pipeline of novel compounds targeting key pathways involved in a range of central nervous system disorders. With several projects in clinical trials, Biohaven is committed to bringing new treatments to market that address unmet medical needs. Its objective is to improve the lives of patients suffering from serious conditions by harnessing the power of cutting-edge science. As of my last update, Biohaven Pharmaceutical is solely listed on the New York Stock Exchange under the ticker symbol (NYSE:BHVN), with a strong dedication to excellence in all aspects of its operations from research to patient care.
Snapshot
Operations
Products and/or services of Biohaven Pharmaceutical Holding Co
- Rimegepant, a CGRP receptor antagonist for migraine treatment, offers rapid relief and can be used for both preventative and acute therapy.
- Zavegepant nasal spray, targeting CGRP receptor for acute migraine treatment, provides an alternative delivery system for patients.
- Troriluzole, a drug for neurodegenerative diseases like Alzheimer's and obsessive-compulsive disorder, aims at modulating glutamate to protect neurological function.
- Verdiperstat, an oral myeloperoxidase inhibitor, focuses on treating multiple system atrophy, aiming to slow disease progression through anti-inflammatory effects.
- BHV-5000, targeting NMDA receptor modulation, is investigated for potential in neuropsychiatric disorders and epilepsy, aiming at a new therapeutic approach.
Biohaven Pharmaceutical Holding Co executive team
- Dr. Vladimir Coric M.D.Chairman & CEO
- Mr. Matthew ButenChief Financial Officer
- Dr. Bruce D. Car DACVP, Ph.D.Chief Scientific Officer
- Ms. Kimberly GentileSenior Vice President of Clinical Operations
- Ms. Deb YoungSenior Director of Regulatory Affairs & Operations
- Mr. George C. Clark CPAVP & Chief Accounting Officer
- Ms. Jennifer PorcelliVice President of Investor Relations
- Mr. Warren Volles J.D.General Counsel & Chief Legal Officer
- Mr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance Officer
- Mr. John TiltonChief Commercial Officer of Rare Diseases